Asthma and Allergic Rhinitis: Understanding the United Airway

The United Airway: One Disease, Two Locations

The nose and the lungs are connected by a single, continuous epithelial surface. From the nasal passages through the pharynx, larynx, trachea, bronchi, and down to the terminal bronchioles, the airway lining shares the same immune cells, the same inflammatory mediators, and the same sensitivity to allergens. The concept of united airway disease reflects this anatomical and immunological reality.

Studies using bronchial challenge testing consistently show that allergen exposure in the nose provokes measurable inflammation in the lungs — even in patients with isolated rhinitis. Conversely, controlling nasal inflammation reduces airway hyper-responsiveness. The two conditions are biologically inseparable in allergic patients.

Why Nasal Inflammation Worsens Asthma

Four distinct mechanisms link upper and lower airway disease:

• Postnasal drip: Inflamed nasal mucosa produces excess mucus that drains posteriorly into the pharynx and is aspirated into the lower airway, delivering allergens and eosinophil-activating cytokines directly to bronchial tissue.
• Mouth breathing: Nasal congestion forces mouth breathing, bypassing the nose's critical filtering, humidifying, and warming functions. Cold, dry, unfiltered air enters the lower airway and triggers bronchospasm.
• Nasobronchial reflex: Nasal mucosal irritation activates a parasympathetic reflex arc that increases bronchial smooth muscle tone via the vagus nerve, narrowing the lower airway independently of direct allergen contact.
• Bone marrow priming: Systemic allergen sensitization activates eosinophil precursors in bone marrow. These cells migrate to both the nasal mucosa and the bronchial wall simultaneously, explaining the simultaneous onset or worsening of both conditions during high-allergen seasons.

Symptom Comparison: Rhinitis vs. Asthma

The two conditions produce distinct but sometimes overlapping symptom profiles. Correct identification of the primary site of inflammation guides treatment choices.

Allergens in South Florida: What Is Driving Your Symptoms?

Broward County's subtropical climate creates one of the highest year-round allergen burdens in the United States. Unlike northern states where pollen seasons are discrete and predictable, South Florida patients are exposed to multiple overlapping allergen sources for twelve months of the year.

ARIA Classification: Severity of Allergic Rhinitis

The Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines classify rhinitis by two dimensions: duration and impact on quality of life. This classification guides treatment intensity.

Diagnosis: Confirming Both Conditions

Accurate diagnosis requires evaluation of both the upper and lower airway, along with allergen sensitization testing to identify specific triggers. At Advanced Asthma Clinic in Plantation, Dr. Frank Hull performs a comprehensive evaluation that typically includes:

Lower Airway Assessment

• Spirometry with bronchodilator response: Confirms obstructive pattern and reversibility consistent with asthma (FEV1/FVC <0.70 with ≥12% and 200 mL improvement post-bronchodilator).
• Fractional exhaled nitric oxide (FeNO): A non-invasive marker of eosinophilic airway inflammation. FeNO ≥40 ppb strongly predicts steroid-responsiveness and T2-high asthma phenotype.
• Methacholine challenge: Confirms bronchial hyper-responsiveness when spirometry is normal at rest; useful for diagnosing mild or atypical asthma.

Upper Airway Assessment

• Clinical history: Onset, seasonality, symptom pattern (morning sneezing = dust mite or mold; outdoor-predominant = pollen; indoor-predominant = pets or cockroach).
• Nasal examination: Pale, boggy, bluish turbinates are characteristic of allergic rhinitis (contrast with the red, swollen turbinates of viral rhinitis).
• Nasal endoscopy: Evaluates for nasal polyps, structural abnormalities, or chronic sinusitis contributing to symptoms.

Allergen Sensitization Testing

• Skin prick testing (SPT): Gold standard. A positive wheal-and-flare response ≥3 mm greater than the negative control confirms IgE-mediated sensitization to that allergen. Results guide allergen avoidance and immunotherapy selection.
• Specific IgE (sIgE) serum testing: Blood test (ImmunoCAP) used when SPT cannot be performed (extensive eczema, dermatographism, antihistamine use, or very severe asthma where SPT carries risk). Quantitative levels (kU/L) correlate with sensitization magnitude.
• Total serum IgE: Elevated in allergic disease; guides omalizumab dosing for patients with allergic asthma who qualify for anti-IgE therapy.

Treatment: A Unified Approach

Because the upper and lower airways share the same inflammatory biology, treatment strategies target common pathways. Medications that reduce nasal inflammation consistently improve asthma outcomes, and vice versa.

Intranasal Corticosteroids (INCS)

INCS — fluticasone propionate (Flonase), mometasone (Nasonex), budesonide (Rhinocort), triamcinolone acetonide (Nasacort) — are the most effective pharmacological treatment for persistent allergic rhinitis. Daily INCS use reduces nasal inflammation, decreases postnasal drip, and has been shown in randomized controlled trials to reduce asthma exacerbations by up to 30%. They are not systemically absorbed in clinically significant amounts at standard doses.

Second-Generation Oral Antihistamines

Cetirizine, fexofenadine, and loratadine block H1 receptors, relieving sneezing, itching, and rhinorrhea. They are less effective than INCS for nasal congestion. They do not significantly improve asthma outcomes when used alone. First-generation antihistamines (diphenhydramine) should be avoided in asthma patients due to their anticholinergic thickening of airway secretions.

Nasal Saline Irrigation

High-volume saline irrigation (neti pot, NeilMed Sinus Rinse) mechanically removes allergens, pollutants, and inflammatory debris from the nasal passages. Studies show it reduces rhinitis symptom scores, decreases INCS requirements, and improves quality of life. It is safe, inexpensive, and evidence-based. Distilled or boiled (cooled) water must be used — tap water carries risk of amoebic infection in rare cases.

Leukotriene Receptor Antagonists (LTRA)

Montelukast (Singulair) blocks leukotriene D4, a potent mediator of both nasal and bronchial inflammation. It is modestly effective for both rhinitis and asthma but less effective than INCS for rhinitis and less effective than ICS for asthma when used alone. Because of its FDA black-box warning for neuropsychiatric events (mood changes, sleep disturbance, suicidal ideation — rare but serious), montelukast is recommended only when preferred alternatives are inadequate or poorly tolerated. Consult your physician.

Inhaled Corticosteroids (ICS) for Asthma

ICS — budesonide, fluticasone, beclomethasone, ciclesonide — remain the cornerstone of asthma controller therapy. They target airway inflammation without meaningful systemic exposure at standard doses. Unlike INCS for rhinitis, ICS do not penetrate the nasal passages in significant amounts; both upper and lower airway treatments are typically required in patients with combined disease.

Combined Treatment Table

Allergen Immunotherapy: The Only Disease-Modifying Option

All medications listed above are symptomatic treatments — they suppress inflammation while you take them but do not change the underlying allergic response. Allergen immunotherapy (AIT) is the only treatment that reprograms the immune system to tolerate allergens. It is disease-modifying: benefits persist for years after completion of the treatment course.

Subcutaneous Immunotherapy (SCIT — Allergy Shots)

SCIT involves injecting gradually increasing doses of purified allergen extract under the skin, typically starting weekly (build-up phase over 6–12 months) then transitioning to monthly maintenance injections for 3–5 years. Injections are given in a clinical setting with a 20–30 minute observation period due to a small risk of systemic allergic reaction. SCIT is FDA-approved and supported by decades of clinical evidence. It reduces rhinitis symptom scores by 30–40%, reduces asthma medication requirements, prevents new allergen sensitizations, and in children reduces the risk of progression from rhinitis-only to asthma by approximately 50%.

Sublingual Immunotherapy (SLIT)

SLIT delivers allergen extract under the tongue daily, either as drops or FDA-approved dissolvable tablets. The nasal mucosa and oral submucosa share immune tolerance mechanisms that make sublingual delivery effective. FDA-approved SLIT tablets include:

• Odactra (ALK) — house dust mite; approved for allergic rhinoconjunctivitis in adults 18–65; also reduces asthma exacerbations in dust mite–sensitized patients
• Grastek (MSD) — timothy grass pollen; approved for grass pollen rhinitis in adults 18–65
• Ragwitek (MSD) — short ragweed pollen; approved for ragweed rhinitis in adults 18–65

SLIT can be taken at home after the first dose (given in clinic with 30-minute observation). It avoids weekly office visits but requires daily adherence for 3–5 years. A 2023 Cochrane review confirmed that dust mite SLIT significantly reduces asthma exacerbations and ICS requirements in dust mite–sensitized patients.

Biologics for Patients With Both Conditions

For patients with moderate-to-severe asthma who also have significant upper airway disease — particularly chronic rhinosinusitis with nasal polyps (CRSwNP) — biologic therapy targeting the shared T2 inflammatory pathway can treat both conditions simultaneously.

Dupilumab (Dupixent) blocks the IL-4 receptor alpha subunit, blocking signaling of both IL-4 and IL-13. It is FDA-approved for both moderate-to-severe asthma (age 6 and up) and CRSwNP (adults). Clinical trials show dupilumab reduces nasal polyp volume, improves nasal symptom scores, reduces annual asthma exacerbation rates by 50–70%, and allows reduction of oral corticosteroid dependence. It is the preferred biologic for patients with combined asthma and nasal polyp disease.

Omalizumab (Xolair) binds free IgE, reducing mast cell and basophil activation across all allergen-driven inflammation. It is FDA-approved for allergic asthma (6 years and older) with confirmed IgE sensitization and an elevated serum IgE. Omalizumab also reduces rhinitis burden, allergic conjunctivitis, and food-triggered reactions. Dosing is based on total IgE level and body weight.

Consult your physician to determine whether a biologic is appropriate for your specific clinical situation.

Allergen Avoidance in South Florida

Avoidance reduces allergen load and decreases the frequency of symptom breakthroughs. In South Florida's climate, completely avoiding key allergens is not possible, but meaningful reduction is achievable:

• Dust mites: Encase mattress and pillows in allergen-impermeable covers. Wash bedding in hot water (≥130°F) weekly. Keep indoor humidity below 50% using air conditioning (standard in South FL). Remove carpeting in bedrooms where possible. HEPA vacuum.
• Mold: Fix water leaks and water intrusion promptly. Exhaust fans in bathrooms and kitchen. Dehumidifiers in basements or enclosed spaces. Avoid composting near bedroom windows. Check AC drip pans for mold growth.
• Cockroach: Seal gaps around plumbing and cabinetry. Store food in sealed containers. Professional pest control. Do not leave dishes or food exposed overnight.
• Pollen: Monitor daily pollen counts (advancedasthmaclinic.com Air Quality resources). Keep windows closed during high-count days. Shower and change clothes after outdoor time during peak season. Wear wraparound sunglasses outdoors.
• Pet dander: Keep pets out of the bedroom. Use HEPA air purifiers in main living areas. Wash hands after pet contact. High-efficiency HVAC filters (MERV 11–13).

When to See a Specialist

A referral to a pulmonologist or allergist/immunologist is appropriate when:

• Rhinitis symptoms persist or worsen despite INCS plus antihistamine therapy
• Asthma is not controlled on step 2 or higher therapy (ICS + LABA)
• You are considering allergen immunotherapy and need skin testing to identify appropriate targets
• You have nasal polyps, recurrent sinusitis, or suspected aspirin-exacerbated respiratory disease (AERD/Samter's Triad)
• You require oral corticosteroids more than twice per year
• You are a candidate for biologic therapy

Dr. Frank Hull at Advanced Asthma Clinic in Plantation, FL offers comprehensive combined upper and lower airway evaluation, allergen sensitization testing, and the full spectrum of asthma and rhinitis management — including biologic therapy and immunotherapy coordination. Consult your physician for personalized guidance.

Related Resources

• Allergic Asthma: IgE-Mediated Airway Disease
• Identifying and Avoiding Your Asthma Triggers
• Mold and Asthma in South Florida
• Asthma and Sinusitis: Managing the Combined Condition
• AERD / Samter's Triad: Aspirin-Exacerbated Respiratory Disease
• Biologic Therapy for Severe Asthma
• Lung Function Testing at Advanced Asthma Clinic